Total Payments
$13,972
2023 Payments
$2,558
Companies
60
Transactions
1,015
Medicare Patients
11,032
Medicare Billing
$1.3M
Payment Breakdown by Category
Food & Beverage$13,931 (99.7%)
Education$40.89 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,931 | 1,009 | 99.7% |
| Education | $40.89 | 6 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $2,051 | 168 | $0 (2023) |
| Amgen Inc. | $2,019 | 150 | $0 (2023) |
| PFIZER INC. | $1,102 | 89 | $0 (2023) |
| Lilly USA, LLC | $974.42 | 75 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $890.99 | 47 | $0 (2023) |
| Merck Sharp & Dohme LLC | $627.10 | 57 | $0 (2022) |
| AbbVie Inc. | $622.65 | 34 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $593.48 | 44 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $525.20 | 41 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $514.66 | 35 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $2,558 | 156 | Novo Nordisk Inc ($382.66) |
| 2022 | $2,361 | 154 | Novo Nordisk Inc ($338.90) |
| 2021 | $2,420 | 170 | Novo Nordisk Inc ($365.81) |
| 2020 | $1,396 | 105 | Amgen Inc. ($228.92) |
| 2019 | $1,494 | 110 | Novo Nordisk Inc ($235.21) |
| 2018 | $1,743 | 139 | Amgen Inc. ($350.45) |
| 2017 | $2,000 | 181 | Novo Nordisk Inc ($320.80) |
All Payment Transactions
1,015 individual payment records from CMS Open Payments — Page 1 of 41
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: Diabetes | ||||||
| 12/07/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $19.08 | General |
| Category: Inflammation | ||||||
| 12/05/2023 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: Bone Health | ||||||
| 12/04/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: Inflammation | ||||||
| 12/01/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: RESPIRATORY | ||||||
| 11/29/2023 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: Central Nervous System | ||||||
| 11/27/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $28.05 | General |
| Category: Rare Disease | ||||||
| 11/23/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/21/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $19.59 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/20/2023 | AbbVie Inc. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $31.22 | General |
| Category: NEUROSCIENCE | ||||||
| 11/17/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: Obesity | ||||||
| 11/16/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: Diabetes | ||||||
| 11/16/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $12.21 | General |
| Category: Diabetes | ||||||
| 11/10/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: Inflammation | ||||||
| 11/09/2023 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $12.08 | General |
| Category: Bone Health | ||||||
| 11/03/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: Diabetes | ||||||
| 11/03/2023 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $5.05 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/02/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $12.94 | General |
| Category: Inflammation | ||||||
| 11/01/2023 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $16.56 | General |
| Category: Diabetes | ||||||
| 10/31/2023 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: Oncology | ||||||
| 10/30/2023 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: PAIN | ||||||
| 10/27/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $31.21 | General |
| Category: NEUROSCIENCE | ||||||
| 10/25/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: Diabetes | ||||||
| 10/24/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $12.02 | General |
| Category: Diabetes | ||||||
| 10/18/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $15.46 | General |
| Category: Obesity | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 37 | 2,650 | 7,949 | $824,480 | $340,688 |
| 2022 | 36 | 2,732 | 8,255 | $818,765 | $342,193 |
| 2021 | 38 | 2,910 | 8,231 | $823,490 | $336,062 |
| 2020 | 40 | 2,740 | 7,772 | $811,345 | $303,797 |
Total Patients
11,032
Total Services
32,207
Medicare Billing
$1.3M
Procedure Codes
171
All Medicare Procedures & Services
171 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 41 | 4,200 | $198,600 | $76,805 | 38.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 526 | 526 | $113,090 | $65,537 | 58.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 335 | 491 | $103,185 | $41,703 | 40.4% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 129 | 157 | $51,410 | $24,300 | 47.3% |
| 99348 | Residence visit for established patient with low level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 176 | 390 | $64,810 | $20,021 | 30.9% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 51 | 270 | $36,700 | $14,401 | 39.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 138 | 194 | $29,360 | $12,092 | 41.2% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 63 | 92 | $16,465 | $7,153 | 43.4% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 145 | 189 | $18,675 | $7,025 | 37.6% |
| 99310 | Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 41 | 54 | $14,245 | $6,342 | 44.5% |
| 99349 | Residence visit for established patient with moderate level of medical decision making, per day, if using time, at least 40 minutes | Office | 2023 | 51 | 74 | $18,535 | $6,113 | 33.0% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Facility | 2023 | 53 | 57 | $14,690 | $5,938 | 40.4% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 82 | 82 | $12,300 | $5,759 | 46.8% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 40 | 40 | $13,700 | $5,697 | 41.6% |
| 99310 | Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Office | 2023 | 35 | 40 | $11,530 | $4,786 | 41.5% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 11 | 11 | $5,880 | $3,097 | 52.7% |
| 91320 | Sarscv2 vac 30mcg trs-suc im | Office | 2023 | 25 | 25 | $6,500 | $3,084 | 47.4% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 18 | 18 | $5,230 | $2,906 | 55.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 95 | 95 | $5,360 | $2,798 | 52.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 48 | 56 | $10,080 | $2,711 | 26.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 93 | 270 | $17,550 | $2,484 | 14.2% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 26 | 29 | $5,080 | $2,245 | 44.2% |
| 99350 | Residence visit for established patient with high level of medical decision making, per day, if using time, at least 60 minutes | Office | 2023 | 18 | 19 | $6,630 | $2,147 | 32.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $5,050 | $1,944 | 38.5% |
| 99342 | Residence visit for new patient with low level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 35 | 35 | $5,720 | $1,896 | 33.2% |
About Dr. Philip Benyo, MD
Dr. Philip Benyo, MD is a Internal Medicine healthcare provider based in Sugarloaf, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1184622391.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Philip Benyo, MD has received a total of $13,972 in payments from pharmaceutical and medical device companies, with $2,558 received in 2023. These payments were reported across 1,015 transactions from 60 companies. The most common payment nature is "Food and Beverage" ($13,931).
As a Medicare-enrolled provider, Benyo has provided services to 11,032 Medicare beneficiaries, totaling 32,207 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 171 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Geriatric Medicine
- Location Sugarloaf, PA
- Active Since 07/12/2005
- Last Updated 01/13/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1184622391
Products in Payments
- Ozempic (Drug) $954.39
- ELIQUIS (Drug) $625.55
- Otezla (Drug) $603.83
- ENTRESTO (Drug) $564.24
- EVENITY (Biological) $508.02
- Prolia (Biological) $475.68
- FARXIGA (Drug) $458.79
- JANUVIA (Drug) $364.92
- TRULICITY (Drug) $326.69
- CHANTIX (Drug) $319.95
- Rybelsus (Drug) $294.52
- JARDIANCE (Drug) $273.82
- Aimovig (Biological) $272.29
- Victoza (Drug) $265.08
- SYMBICORT (Drug) $255.92
- TRELEGY ELLIPTA (Drug) $254.58
- UBRELVY (Drug) $227.92
- MOUNJARO (Drug) $222.99
- SOLIQUA (Drug) $212.79
- Kerendia (Drug) $207.55
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.